Moody Aldrich Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Moody Aldrich Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-96,237	Closed	-$3.59M	–	191
2021 Q2	$3.59M	Sell	96,237 -1,219	-1%	-$37.4K	0.5%	80
2021 Q1	$2.49M	Buy	97,456 +1,438	+1%	+$36.7K	0.36%	88
2020 Q4	$2.12M	Buy	96,018 +47	+0%	+$1.03K	0.34%	89
2020 Q3	$1.73M	Buy	95,971 +2,303	+2%	+$47.7K	0.36%	90
2020 Q2	$2.38M	Buy	93,668 +13,826	+17%	+$298K	0.51%	77
2020 Q1	$1.47M	Sell	79,842 -119	-0.1%	-$2.31K	0.44%	82
2019 Q4	$1.76M	Buy	+79,961	New	+$1.61M	0.36%	92

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Moody Aldrich Partners's DRNA Position: Q3 2021 in Review

Moody Aldrich Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 96,237 shares — an estimated $3.59M sold.

Moody Aldrich Partners first reported a position in DRNA in Q4 2019 and held it in 7 quarters. The position peaked at $3.59M in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Moody Aldrich Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Moody Aldrich Partners sold 96,237 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $3.59M.
Moody Aldrich Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 7 quarters.
Moody Aldrich Partners's Dicerna Pharmaceuticals, Inc. position peaked at $3.59M in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Moody Aldrich Partners's 13F filing for Q3 2021, filed 29 Oct 2021.